Press Kit
Salvat at a glance
If you are a media professional and wish to receive more information, please send us an email at media@svt.com.
Salvat’s News and Press kit
Media
Salvat at a glance
Press Kit
What are we doing right now
News
Media
Salvat’s News and Press kit
Media
Salvat at a glance
Press Kit
What are we doing right now
News
Media
Salvat at a glance
If you are a media professional and wish to receive more information, please send us an email at media@svt.com.
English Version PDF
What are we doing right now
These cookies collect information about how visitors make use of the website, such as page views, loading errors… It is generic and anonymous information where personal data are not included nor collects information that identifies visitors; with the ultimate aim to improve the functioning of the website.
| Cookie | Duration | Description |
|---|---|---|
| _ga | 2 years | Google Analytics |
| _gat_gtag_UA_112188601_1 | 2 years | Google Analytics |
| _gid | 2 years | Google Analytics |
These cookies are necessary for the proper use of the website, allowing access to sections that have security filters. Without these cookies, many of the features would not be operating.
| Cookie | Duration | Description |
|---|---|---|
| cookielawinfo-checbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| ip2location_redirection_first_visit | session | Mostrar las páginas de la web en el idioma seleccionado / Browse this website pages in the selected language |
| PHPSESSID | session | Identificador de sesión PHP / PHP session id |
| prescriptionModalAccepted | session | Identificador de sesión PHP / PHP session id |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
| wpml_browser_redirect_test | session | Mostrar las páginas de la web en el idioma seleccionado / Browse this website pages in the selected language |
| _icl_visitor_lang_js | session | Mostrar las páginas de la web en el idioma seleccionado / Browse this website pages in the selected language |
Herpix®, the new oral formula against the Herpes Simplex Virus from Laboratorios Salvat, is chosen as Product of the Year 2021
/in Salvat International, Salvat Spain, Salvat USA /by Carme LopezThe new product from Laboratorios Salvat has been recognised as this year’s most innovative Food Supplement for the Immune System Herpix® is a food supplement formulated from natural extracts which helps slow the replication of the Herpes Simplex Virus (HSV), acting from the inside right from the appearance of the first symptom Herpix®, the new […]
Salvat pioneers advancement in the treatment of non-consolidated bone fractures (BONECURE project)
/in Salvat International, Salvat Spain, Salvat USA /by Carme LopezSalvat’s new BONECURE project is an innovative medical advancement based on pre-differentiated mesenchymal cells designed to treat patients with bone consolidation problems post-fracture (atrophic pseudoarthrosis). A Phase II clinical trial is being completed with promising results in terms of both efficacy and safety, in patients with long bone pseudoarthrosis. Salvat has conducted this project in […]
Cristalmina increases production sevenfold and prepares to launch in international market
/in Salvat International, Salvat Spain, Salvat USA /by Carme LopezA new automated robotic line costing more than €6 million has enabled Cristalmina to increase production from 2.5 million to 15 million units per year By 2021, the company plans to have authorisation to market Cristalmina in more than 26 European countries, which will be followed by Asia and the USA in the years to […]
The Spanish Ministry of Industry maintains the rating of “VERY GOOD” to Laboratorios Salvat SA in the PROFARMA 2019 program
/in Salvat Spain /by Carme LopezAgain this year, Laboratorios Salvat, S.A. has been granted with the rating “VERY GOOD” by the PROFARMA 2019 program of the Spanish Ministry of Industry, which values pharmaceutical companies based on their excellence in Industrial, economic and Research, Development and Innovation activities. This qualification represents an important recognition of Salvat’s continued efforts towards its objective […]
Laboratorios Salvat leads the development of the first treatment for otomycosis
/in Salvat International, Salvat Spain, Salvat USA /by Carme LopezThe research, currently underway both in the United States of America and Europe, will involve an investment of more than $10 million. The worldwide launch of the new medicament to treat this type of external otitis, expected for the end of 2021, reinforces Salvat’s positioning in otology at an international level. The company’s international business […]